UCLA researchers found that boosting p53 protein with navtemadlin helped T cells fight melanoma cancer cells longer, but dosing challenges remain.

Researchers at Roswell Park Comprehensive Cancer Center have identified a promising strategy for overcoming one of the biggest challenges facing KRAS-targeted cancer therapies: treatment resistance.

Dr. Elizabeth Comen explains why managing side effects, speaking up about challenges and protecting your quality of life are ...

By Dennis Thompson HealthDay ReporterMONDAY, Oct. 26, 2026 (HealthDay News) — Starting survivorship care for patients with ...

Eleventh annual fundraising effort brings Lendmark’s cumulative total to more than $12.4 million raised for pediatric cancer research and family supportLAWRENCEVILLE, Ga., Nov. 02, 2026 (GLOBE ...

A headline about a "breakthrough cancer vaccine" is bound to raise a big question: Can it actually cure cancer? That's what many patients are wondering after Moderna and Merck announced promising ...

Learn how colon cancer treatment varies by stage, from surgery for early disease to chemotherapy, targeted therapy, and ...

Nicole Eggert opened up about the financial toll of her cancer battle and being unable to work while raising her teenage daughter.

The Decipher genomic test could help doctors decide which high-risk prostate cancer patients need abiraterone hormone therapy ...

Scientists at the University of North Carolina Lineberger Comprehensive Cancer Center have discovered an unexpected role for a key innate immune protein, revealing how it helps regulate cholesterol ...